Journals / Sakarya Tıp Dergisi / 2020 / Cilt: 10 - Sayı: 1

Current Approach to Hereditary Angioedema at Emergency Department

Acil Serviste Herediter Anjioödem’e Güncel Yaklaşım

Pages
152–161
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Among four attack treatment options, plasma-derived C1-INH concentrate, recombinant C1-INH concentrate, ecallantide, and icatibant are utilized nowadays.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Hereditary angioedema (HAE) is an uncommon, mostly due to C1 inhibitor (C1-INH) deficiency, possibly fatal disorder known by episodic angioedema attacks with autosomal dominant inheritance.
📊
Key Findings & Data:Erythme marginatum-like rash is seen in 1/3 of the patients during prodromal period.
💡
Conclusion & Impact:Among four attack treatment options, plasma-derived C1-INH concentrate, recombinant C1-INH concentrate, ecallantide, and icatibant are utilized nowadays.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Hereditary angioedema (HAE) is an uncommon, mostly due to C1 inhibitor (C1-INH) deficiency, possibly fatal disorder known by episodic angioedema attacks with autosomal dominant inheritance. Angioedema attacks are generally sudden, often unpredictable and causing swelling typically affecting the extremities, trunk, face, abdomen, genitalia, and upper airways. Erythme marginatum-like rash is seen in 1/3 of the patients during prodromal period. Since HAE patients characteristically have no concomitant urticaria, they are frequently considered as nonhistaminergic (bradykinergic) angioedema. Attacks may lead to significant functional impairment, decreased quality of life, and fatality due to laryngeal attacks. Abdominal attack of HAE usually resembles several acute abdominal situations, such as familial mediterranean fever (FMF) and appendicitis causing a deferral of exact diagnosis and unfitting therapies. Treatment for HAE involves long- and short-term prophylaxis as well as management of attacks. Among four attack treatment options, plasma-derived C1-INH concentrate, recombinant C1-INH concentrate, ecallantide, and icatibant are utilized nowadays.

Özet

Herediter anjioödem (HAÖ) nadir görülen, genelde C1 inhibitör (C1-INH) eksikliğine bağlı, tekrarlayan anjioödem ataklarıyla bilinen ve ölümcül olabilen otozomaldominant geçişli bir hastalıktır. Anjioödem atakları genellikle aniden oluşur, sıklıkla tahmin edilemez ve tipik olarak ekstremite, gövde, yüz, karın, genital organlar veüst solunum yollarını tutan şişliklere yol açar. Hastaların yaklaşık 1/3’ünde prodromal dönemde eritema marginatum benzeri döküntü görülebilir. Herediter anjioödemhastalarında tipik olarak eşlik eden ürtiker olmaması sıklıkla nonhistaminerjik (bradikinerjik) anjioödem şeklinde düşünülmesine yol açar. Ataklar önemli derecedeişlevsel bozukluğa, yaşam kalitesinin azalmasına ve larengeal atak olgularında ise ölüme yol açabilir. Herediter anjioödemin karın tutulumuyla giden atağı genelde tanıdagecikme ve uygunsuz tedaviye neden olan ailevi Akdeniz ateşi (AAA) ve apandisit gibi bazı akut batın durumlarını taklit eder. Herediter anjioödem tedavisi kısa ve uzunsüreli profilaksi ile atak tedavilerini içerir. Günümüzde kullanılan dört tür akut/atak tedavi seçeneği arasında, plazma kaynaklı C1-INH konsantresi, rekombinant C1-INHkonsantresi, ecallantide ve ikatibant sayılabilir.

🔖

Cite This Article

Özdemir, Ö. (2022). Current Approach to Hereditary Angioedema at Emergency Department. Sakarya Tıp Dergisi, Cilt: 10 - Sayı: 1, 152–161. https://ajindex.com/articles/590421

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Özdemir Ö. Herediter anjioödemde tanı ve ayırıcı tanı. Turkiye Klinikleri J Allergy-Special Topics 2011;4(2):21-35
  2. Kelly M, Donnelly JP, McAnnally JR, Wang HE. National estimates of emergency department visits for angioedema and allergic reactions in the United States. Allergy Asthma Proc. 2013;34:150–4
  3. Bertazzoni G, Spina MT, Scarpellini MG, Buccelletti F, De Simone M, Gregori M, et al. Drug-induced angioedema: experience of Italian emergency departments. Intern Emerg Med. 2014;9:455–62
  4. Felder S, Curtis RM, Ball I, Borici-Mazi R. Prognostic factors in outcome of angioedema in the emergency department. Allergy Asthma Proc. 2014; 35(5):362-70
  5. Bernstein JA, Cremonesi P, Hoff mann TK, Hollingsworth J. Angioedema in the emergency department: a practical guide to diff erential diagnosis and management. Int J Emerg Med. 2017; 10(1):15
  6. Bowen T, Cicardi M, Farkas H, Bork K, Longhurst HJ, Zuraw B, et al. 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol. 2010; 6(1):24
  7. Özdemir Ö, Elmas B. Türkiye’de bir şehirde indeks herediter anjioödem hastalarının uzak ve yakın test edilmemiş akrabalarında herediter anjioödem prevalans ve klinik belirtileri. JAREM 2017; 7:51-7
  8. Zuraw BL. Hereditary angioedema with normal C1 inhibitor: Four types and counting. J Allergy Clin Immunol. 2018; 141(3):884-5
  9. Lumry WR. Overview of epidemiology, pathophysiology, and disease progression in hereditary angioedema. Am J Manag Care. 2013; 19(7 Suppl):s103-10
  10. Gülbahar O, Gelincik A, Sin A, Güleç M, Yılmaz M, Gökmen NM, et al. Herediter anjioödem. Asthma Allergy Immunol 2010; 8: 125–38
  11. Zuraw BL, Christiansen SC. HAE pathophysiology and underlying mechanisms. Clin Rev Allergy Immunol. 2016;51(2):216-29
  12. Özdemir Ö. Innovations in Hereditary Angioedema Pathophysiology. South. Clin. Ist. Euras. 2019;30(4):355-361 13. Ozdemir O. New developments in type of hereditary angioedema with normal CI-inhibitor level. MOJ Immunol. 2019;7(1):1‒2
  13. Dewald G, Bork K. Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. Biochem Biophys Res Commun 2006; 343:1286-9
  14. Bork K, Wulff K, Steinmüller-Magin L, Braenne I, Staubach-Renz P, Witzke G, et al. Hereditary angioedema with a mutation in the plasminogen gene. Allergy 2018; 73(2):442- 50
  15. Bafunno V, Firinu D, D’Apolito M, Cordisco G, Loff redo S, Lecces